The gold industry standard for risk and cost of drug and vaccine development revisited
- 1 August 2011
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 29 (35), 5846-5849
- https://doi.org/10.1016/j.vaccine.2011.06.051
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Estimated research and development costs of rotavirus vaccinesVaccine, 2009
- Portfolio analysis and R&D decision makingNature Reviews Drug Discovery, 2009
- The 'not invented here' mythNature Reviews Drug Discovery, 2006
- Estimating The Cost Of New Drug Development: Is It Really $802 Million?Health Affairs, 2006
- How can we avoid the productivity gap?Drug Discovery Today, 2005
- Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliancesJournal of Health Economics, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- The New Drug Approvals of 1999, 2000, and 2001: Drug Development Trends a Decade after Passage of the Prescription Drug User Fee Act of 1992Drug Information Journal, 2003
- Vaccine R&D success rates and development timesNature Biotechnology, 1996